US FDA approval of AstraZeneca PLC's Imfinzi (durvalumab) for non-small cell lung cancer is important in two big respects – it is the drug's first clearance in this valuable tumor type and it is the first in such an early line of therapy for a PD-1/L1 inhibitor.
FDA announced approval of Imfinzi on Feb. 16 for patients with Stage III non-small cell lung cancer (NSCLC) whose tumors...






